LaSara Medical Group review

The costs at a glance

Start with the product menu, then ask about setup costs

LaSara Medical Group's semaglutide product page gives shoppers several concrete choices: $299 for one month and a separately labeled $289 monthly subscription. That is a useful distinction because a one-time purchase and automatic renewal need not have the same price or obligations. My concern is whether either amount represents the complete first bill. LaSara's separate cost article describes a substantial initiation fee, while another page advertises a lower starting price. I would keep the one-month product listing as the clearest comparison reference and ask for the actual enrollment total before relying on it.

Longer terms reduce the average, not the cash due

The semaglutide menu lists $849 for three months, $1,495 for six and $2,795 for twelve. Those are different commitments, not interchangeable versions of a month-to-month offer. Ask whether payment is collected upfront, how medication is dispensed over the term and what happens if the clinician changes the plan. A longer package may lower the average cost while increasing the amount exposed to a restrictive refund policy. Compare the shortest acceptable term first, then decide whether the additional discount is worth committing more money before you know how the care arrangement works for you. Compare the full payment schedule in our plan budget tool before choosing a term.

The cost article describes another first-month calculation

LaSara's cost article says there is a $597 setup fee covering intake and plan development, a $99 first medication month and $299 monthly afterward. If both initial charges apply, the starting outlay would be $696 before any other applicable item. That arithmetic is not a quote for the current product-page offer; it shows why the discrepancy matters. Request a yes-or-no answer about the initiation fee for the exact plan you are considering. Do not quietly remove a published charge from your comparison simply because it is absent from a shorter product description elsewhere on the site.

A lower about-page figure needs its own explanation

The about page advertises semaglutide starting at $179 per month. Its surrounding company story does not explain how that figure maps to the product menu or the cost article's setup structure. I would not use it as the headline treatment budget without a matching offer and term. Ask whether it belongs to a different dose, promotion or discontinued arrangement. This is a practical transparency issue rather than evidence about treatment quality. A provider can resolve it with a clear current quote; until then, a shopper should retain all three figures and avoid assuming the lowest one is available.

Tirzepatide is a separate comparison with a higher outlay

LaSara's tirzepatide product page lists $399 for one month and $379 for the monthly subscription. Multi-month totals are $1,100 for three, $1,995 for six and $3,895 for twelve. Keep those figures separate from the semaglutide offer. The correct medication decision belongs with the prescriber, while your comparison should show the financial consequences of each proposed option. Ask whether a switch changes an existing prepaid balance or starts another purchase. A marketing description of stronger results is not enough reason to choose the larger commitment before discussing suitability, tolerance and the ongoing care plan.

The clinic’s protocol name does not establish product approval

LaSara describes physician-guided compounded treatment and pharmacy sourcing. A compounded prescription should still be identified by its actual ingredients, concentration, dispensing pharmacy and instructions. The existence of a clinic protocol or a pharmacy certification does not turn the compounded product into an FDA-approved branded medicine. Ask the clinician to explain the prescribed formulation and the reason for choosing it. I would also ask which laboratory work is required and how results are reviewed, rather than assuming that every form of monitoring mentioned in marketing is included in every package or delivered on the same schedule. Bring our telehealth appointment checklist to the clinical conversation.

Financing and flexibility need a full cancellation answer

The cost article discusses financing and payment options, while product pages say patients can cancel or pause. Neither description alone establishes the refund on an unused part of a multi-month purchase. If you finance a package, ask whether cancellation of clinical care changes the financing balance. Also request the cutoff for stopping an order already sent to the pharmacy and the treatment of an initiation fee. Keep the payment agreement alongside the service terms. An affordable installment is only helpful when you understand the total obligation and the circumstances under which the remaining payments still continue. Our guide to GLP-1 cancellation and refund policies explains the differences between stopping renewal and recovering an existing payment.

Who should consider LaSara?

LaSara may suit someone who wants a physician-led program with visible product choices and is willing to resolve the conflicting price pages before committing. I would favor a written itemized quote showing the selected medication, term, dose coverage, setup charge, required testing and renewal rules. Compare that total with another provider offering the same kind of care, rather than ranking LaSara by its lowest advertised number. The published range of payment periods is useful, but it does not replace clarity about the first bill. A responsive explanation of the discrepancies should be part of the decision. For a separate cash-pay comparison, see our Eden review and compare the complete selected plan.

Before you sign up

• Does the $597 initiation fee apply to this product?
• Is $289 the recurring subscription price for my selected dose?
• What is refundable on a prepaid plan if treatment changes?

Use the answers to compare the exact offer with another provider. A service review cannot determine whether a medication is appropriate for you; that decision belongs with your clinician.